A compressed sensing approach to immobilized nanoparticle localization for superparamagnetic relaxometry

Superparamagnetic relaxometry (SPMR) exploits the unique magnetic properties of targeted superparamagnetic iron oxide nanoparticles (SPIOs) to detect small numbers of cancer cells. Reconstruction of the spatial distribution of cancer-bound nanoparticles requires solving an ill-posed inverse problem. The current method, multiple source analysis (MSA), uses a least-squares fit to determine the strength and location of a pre-determined number of magnetic dipoles. In this proof-of-concept study, we propose the application of a sparsity averaged reweighting algorithm (SARA) for volumetric reconstruction of immobilized nanoparticle distributions. We first calibrate the parameters that define the location of the sensors in the forward model of measurement physics. Using this optimized model, we evaluated the performance of the algorithms on various configurations of single and multiple point-source phantoms. We investigated the effect of the data fidelity parameter, voxel size, and iterative reweighting on the reconstruction produced by SARA. We found that the calibrated physics model can predict the detected field values within 5% of the measured data. When only a single source was present, both algorithms were able to detect as little as 0.5 µg of immobilized particles. However, when two sources were measured simultaneously, MSA failed to detect sources containing as much as 10 µg of particles, while SARA detected all of the sources containing at least 5 µg of particles. We show that a suitable data fidelity parameter can be selected objectively, and the total magnitude and location of a point source reconstructed by SARA is not sensitive to voxel size. Detection and localization of multiple small clusters of nanoparticles is a crucial step in SPMR-based diagnostic applications. Our algorithm overcomes the need to know the number of dipoles before reconstruction and improves the sensitivity of the reconstruction when multiple sources are present.

Screening for ovarian cancer: imaging challenges and opportunities for improvement

The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) recently reported a reduction in the average overall mortality among ovarian cancer patients screened with an annual sequential, multimodal strategy that tracked biomarker CA125 over time, where increasing serum CA125 levels prompted ultrasound. However, multiple cases were documented wherein serum CA125 levels were rising, but ultrasound screens were normal, thus delaying surgical intervention. A significant factor which could contribute to false negatives is that many aggressive ovarian cancers are believed to arise from epithelial cells on the fimbriae of the fallopian tubes, which are not readily imaged. Moreover, because only a fraction of metastatic tumors may reach a sonographically-detectable size before they metastasize, annual screening with ultrasound may fail to detect a large fraction of early-stage ovarian cancers. The ability to detect ovarian carcinomas before they metastasize is critical and future efforts towards improving screening should focus on identifying unique features specific to aggressive, early-stage tumors, as well as improving imaging sensitivity to allow for detection of tubal lesions. Implementation of a three-stage multimodal screening strategy in which a third modality is employed in cases where the first-line blood-based assay is positive and the second-line ultrasound exam is negative may also prove fruitful in detecting early-stage cases missed by ultrasound.

Prevention of type 1 diabetes

INTRODUCTION/BACKGROUND

Type 1 diabetes is a chronic autoimmune condition characterized by destruction of insulin-producing β cells within the pancreatic islets. It is associated with considerable morbidity and mortality. Incidence levels are rising worldwide.

SOURCES OF DATA

Pubmed search (Nov 2010) using keywords: Type 1 diabetes, prevention, trials, immunotherapy.

AREAS OF AGREEMENT

The causes of disease are multifactorial with genetic and environmental factors playing a part. There is a long pre-clinical period before the onset of overt symptoms, which may be amenable to therapeutic intervention to prevent disease.

AREAS OF CONTROVERSY

The exact nature of causative environmental factors is unknown and much debated. Immunotherapeutic intervention may therefore represent the best option for disease prevention.

GROWING POINTS

Enhancement of 'regulatory' immune mechanisms currently shows the most promise as an approach to disease prevention.

AREAS TIMELY FOR DEVELOPING RESEARCH

Clinical trials of early immunotherapeutic intervention may be the answer to disease prevention.

Strategies to prevent type 1 diabetes

Type 1 diabetes is a chronic autoimmune condition resulting from T cell-mediated destruction of the insulin-producing cells in the islets of Langerhans. Its primary cause remains unknown, but it has been established that the clinical presentation is preceded by a long prodrome. This enables individuals at high risk of disease to be identified and offers the possibility of intervention to prevent clinical disease. Many groups are working in this field, concentrating on manipulation of environmental exposures that are potential triggers of autoimmunity and on immunomodulation strategies that aim to prevent destruction of beta-cells. Some interventions have shown promising results in early trials, but effective disease prevention remains elusive. This article reviews current progress in the field.

Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study

Immunotherapeutic strategies under consideration for type 1 diabetes include modification of the autoimmune response through antigen-specific routes. Administration of short peptides representing T cell epitopes targeted by patients with the disease represents one approach. This study evaluated safety and mechanistic outcomes during first-in-man intradermal administration of a human leucocyte antigen-DR4 (HLA-DR4)-restricted peptide epitope of proinsulin (C19-A3). This randomized, open-label study assessed two major theoretical risks of peptide immunotherapy, namely induction of allergic hypersensitivity and exacerbation of the proinflammatory autoimmune response, using clinical assessment and mechanistic assays in vitro. Patients with long-standing type 1 diabetes and HLA-DRB1*0401 genotype received 30 microg (n = 18) or 300 microg (n = 18) of peptide in three equal doses at 0, 1 and 2 months or no intervention (n = 12). Proinsulin peptide immunotherapy in the dosing regimen used is well tolerated and free from risk of systemic hypersensitivity and induction/reactivation of proinsulin-specific, proinflammatory T cells. Peptide-specific T cells secreting the immune suppressive cytokine interleukin (IL)-10 were observed at month 3 in four of 18 patients in the low-dose group (versus one of 12 in the control group; P = not significant). Mean IL-10 response to peptide in the low-dose group increased between 0 and 3 months (P = 0.05 after stimulation with 5 microM peptide in vitro) and then declined to baseline levels between 3 and 6 months (P = 0.01 at 10 microM peptide in vitro). These studies pave the way for future investigations in new-onset patients designed to examine whether proinsulin peptide immunotherapy has beneficial effects on markers of T cell autoimmunity and preservation of beta cell mass.

Utility of Mini-Mental State Exam scores in predicting functional impairment among white and African American dementia patients

BACKGROUND

The Mini-Mental State Exam (MMSE) is widely used to assess cognitive impairment. Although education and race have been shown to affect the validity of the MMSE in detecting dementia, whether race and education influence the validity of the MMSE in gauging severity of dementia is unknown.

METHODS

Patients diagnosed with Alzheimer's and other dementias (59 African American, 112 White) were administered the MMSE, and information was gathered on patient functional impairment, including Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), and the Memory and Behavior Problems Checklist (MBPC). Demographic information, including patient and caregiver education, and patient age, was also assessed.

RESULTS

African American and White patients did not differ significantly on the MMSE or functional impairment variables, but White patients had higher educational attainment. Hierarchical multiple regression analysis showed that race and education did not predict functional impairment, and MMSE scores were strong predictors of ADL and IADL levels for both African American and White patients. MMSE predicted variability in MBPC scores for White patients only, perhaps related to racial differences in subjective caregiver report of behavioral problems.

CONCLUSIONS

While race and education may affect the validity of the MMSE in detecting the presence of cognitive impairment, the MMSE can be a useful predictor of degree of ADL and IADL impairment in patients diagnosed with dementia, regardless of race.